XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Derivative Instruments (Tables)
3 Months Ended
Mar. 31, 2019
Summary of Derivative Instruments [Abstract]  
Summary Of The Effect Of Derivative Instruments On The Consolidated Statements Of Changes In Equity And Income
Below is a summary of the effect of derivative instruments on the consolidated statements of changes in equity and income for the three months ended March 31, 2019 and 2018.
 
Effect of Derivative Instruments on the Consolidated Statements of Changes in Equity and Income for the Three Months Ended March 31, 2019 and 2018
(Dollars in thousands)
 
Three Months Ended March 31,
 
Description
2019
 
2018
 
Cash Flow Hedges
 
 
 
 
Interest Rate Swaps
 
 
 
 
Amount of (Loss) Gain Recognized in AOCI on Derivative
$
(2,439
)
 
$
4,778

 
Amount of Income (Expense) Reclassified from AOCI into Earnings (1)
775

 
(13
)
 
Cross-Currency Swaps
 
 
 
 
Amount of (Loss) Gain Recognized in AOCI on Derivative
(311
)
 
615

 
Amount of Income Reclassified from AOCI into Earnings (2)
134

 
554

 
 
 
 
 
 
Net Investment Hedges
 
 
 
 
Cross-Currency Swaps
 
 
 
 
Amount of Loss Recognized in AOCI on Derivative
(3,839
)
 

 
Amount of Income Recognized in Earnings (2) (3)
138

 

 
Currency Forward Agreements
 
 
 
 
Amount of Gain Recognized in AOCI on Derivative

 
4,546

 
Amount of Expense Reclassified from AOCI into Earnings (2)

 

 
 
 
 
 
 
Total
 
 
 
 
Amount of (Loss) Gain Recognized in AOCI on Derivatives
$
(6,589
)
 
$
9,939

 
Amount of Income Reclassified from AOCI into Earnings
909

 
541

 
Amount of Income Recognized in Earnings
138

 

 
 
 
 
 
 
Interest expense, net in accompanying consolidated statements of income
33,826

 
34,337

 
Other income in accompanying consolidated statements of income
344

 
630

 
(1)
Included in "Interest expense, net" in the accompanying consolidated statements of income for the three months ended March 31, 2019 and 2018.
(2)
Included in "Other income" in the accompanying consolidated statements of income for the three months ended March 31, 2019 and 2018.
(3)
Amounts represent derivative gains excluded from the effectiveness testing.